Home » Stocks » DRRX

DURECT Corporation (DRRX)

Stock Price: $2.22 USD -0.05 (-1.99%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $2.18 -0.04 (-1.80%) Feb 26, 7:57 PM
Market Cap 498.37M
Revenue (ttm) 41.99M
Net Income (ttm) -9.17M
Shares Out 201.88M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $2.22
Previous Close $2.27
Change ($) -0.05
Change (%) -1.99%
Day's Open 2.26
Day's Range 2.12 - 2.30
Day's Volume 2,377,703
52-Week Range 0.95 - 2.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 3 weeks ago

Market Watch - 3 weeks ago

Shares of Durect Corp. gained 34.3% in premarket trading on Tuesday after the company said its drug, Posimer, had been approved by the Food and Drug Administration as a treatment for pain afte...

PRNewsWire - 3 weeks ago

CUPERTINO, Calif., Feb. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has approved POSIMIR® (bupivacaine solution) ...

GuruFocus - 3 weeks ago

Investors who target growth could be interested in the following small-cap stocks, as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-o...

Other stocks mentioned: HONE, INSW
PRNewsWire - 1 month ago

CUPERTINO, Calif., Jan. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the sale of the LACTEL product line to Evonik closed and the $15 million payment was rece...

PRNewsWire - 2 months ago

CUPERTINO, Calif., Dec. 7, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has signed an agreement to sell its LACTEL Absorbable Polymer (LACTEL) product line to...

PRNewsWire - 3 months ago

CUPERTINO, Calif., Nov. 13, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today presented additional safety data and efficacy signals from its Phase 1b clinical trial of DUR-928 in no...

Seeking Alpha - 3 months ago

DURECT Corporation (DRRX) CEO Jim Brown on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -23.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 3 months ago

CUPERTINO, Calif., Nov. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on the development of treatments for acute organ injury and chronic liver...

Zacks Investment Research - 3 months ago

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: CI, CWBR, GRFS, PTI
PRNewsWire - 4 months ago

CUPERTINO, Calif., Oct. 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in the ROTH Capital Healthcare Event, "Covid-19 Therapeutics in Develo...

Zacks Investment Research - 4 months ago

Durect (DRRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 5 months ago

CUPERTINO, Calif., Sept. 30, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. W...

PRNewsWire - 6 months ago

CUPERTINO, Calif., Aug. 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E.

InvestorPlace - 6 months ago

As we head further into August, a handful of penny stocks look like good opportunities. That said, here's seven penny stocks to buy.

Other stocks mentioned: SKYS, NGD, PRTY, SEAC, UMC, ZSAN
Seeking Alpha - 6 months ago

DURECT Corporation (DRRX) CEO Jim Brown on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Durect (DRRX) delivered earnings and revenue surprises of 75.00% and 30.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 6 months ago

CUPERTINO, Calif., Aug. 3, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2020 and provided a corporate update.

The Motley Fool - 7 months ago

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

Other stocks mentioned: NLTX, RLMD
PRNewsWire - 8 months ago

CUPERTINO, Calif., June 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Gilead Sciences, Inc., (Gilead) has provided notice that, effective as of December 22, 2...

Seeking Alpha - 9 months ago

DURECT Corporation: DUR-928 May Benefit COVID-19 Patients With Acute Organ Injury

The Motley Fool - 9 months ago

The biotech becomes a COVID-19 play and benefits from a competitor's failure.

Seeking Alpha - 9 months ago

DURECT Corp (DRRX) CEO James Brown on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -41.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 10 months ago

Durect Is A Biotech To Watch With Key Catalysts In 2020

Seeking Alpha - 11 months ago

DURECT Corporation (DRRX) CEO Jim Brown on Q4 2019 Results - Earnings Call Transcript

InvestorPlace - 1 year ago

While some argue you get what you pay for, others say that stocks trading at low levels can represent compelling opportunities.

Other stocks mentioned: MTNB, NOG, TAST, VBIV
Seeking Alpha - 1 year ago

Eli Lilly's Acquisition Strategy, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: LLY, HSDT
24/7 Wall Street - 1 year ago

Durect Corp. (NASDAQ: DRRX) shares dropped early on Friday after the U.S. Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) announced its vote on ...

Market Watch - 1 year ago

Biopharmaceutical company Durect Corp. DRRX, +3.25% said Friday a U.S. Food and Drug Administration committee ended a meeting to review its Posimir treatment for post-surgical pain with a spli...

Market Watch - 1 year ago

Shares of biopharmaceutical company Durect Corp. DRRX, +3.25% were halted Thursday, ahead of a U.S.

The Motley Fool - 1 year ago

Seven biotechs led the way.

Other stocks mentioned: ARQL, AXSM, CNST, EVER, ISEE, KOD, PRVB, RCEL, SSI
The Motley Fool - 1 year ago

The biotech's midstage study of DUR-928 failed, but the drug isn't dead yet.

Market Watch - 1 year ago

Shares of Durect Corp. DRRX, -29.64% tumbled 34% on Thursday morning after the biopharmaceutical company said it would stop development of DUR-928 as a treatment for psoriasis.

The Motley Fool - 1 year ago

Investors jump in ahead of a binary event.

Seeking Alpha - 1 year ago

DURECT Corp (DRRX) CEO James Brown on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

DURECT Corporation has a promising drug, DUR-928, a sulfated oxysterol that is being studied in alcoholic hepatitis, NASH and psoriasis.

The Motley Fool - 1 year ago

Hardly anyone's heard of these drugmakers, but some analysts think they could be top performers.

Other stocks mentioned: KDMN
The Motley Fool - 1 year ago

Investors bid up the share price after the company received some bullish praise from a Wall Street pro.

Seeking Alpha - 1 year ago

DURECT Corporation (DRRX) CEO Jim Brown on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

DURECT established a deal with Gilead Sciences with potential to earn $320 million or more in payments to develop HIV and Hepatitis B products.

Seeking Alpha - 1 year ago

DURECT announced a deal with Gilead to out-license its SABER® technology for a Long-Acting Injectable HIV Investigational Product.

Other stocks mentioned: GILD
Benzinga - 1 year ago

Penny stock DURECT Corporation (NASDAQ: DRRX) is advancing strongly Monday following an out-licensing deal with Gilead Sciences, Inc.

Seeking Alpha - 1 year ago

DURECT Corp (DRRX) CEO James Brown on Q1 2019 Results - Earnings Call Transcript

About DRRX

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, su... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Sep 28, 2000
CEO
James Brown
Employees
95
Stock Exchange
NASDAQ
Ticker Symbol
DRRX
Full Company Profile

Financial Performance

In 2019, DRRX's revenue was $29.56 million, an increase of 59.25% compared to the previous year's $18.56 million. Losses were -$20.58 million, -18.73% less than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for DRRX stock is "Strong Buy." The 12-month stock price forecast is 6.67, which is an increase of 200.45% from the latest price.

Price Target
$6.67
(200.45% upside)
Analyst Consensus: Strong Buy